Product details
Background：Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011).
• Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site., PMID:9178760
• Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias., PMID:9130617
• Identification of AXL as a co-receptor for human parvovirus B19 infection of human erythroid progenitors., PMID:36630517
• The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer., PMID:25568918
• Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia., PMID:39395205
• Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain., PMID:8108112
• Serum AXL is a potential molecular marker for predicting COVID-19 progression., PMID:38799467
• Clinical significance of AXL kinase family in gastric cancer., PMID:12168903
• Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells., PMID:21730355
• The genomic structure of the human UFO receptor., PMID:8381225
